Penn Pharma

About Penn Pharma

In 1979, a new player emerged in the UK pharmaceutical services landscape: Penn Pharma. For decades, the company operated as a contract development and manufacturing organization, providing essential drug development, manufacturing, and clinical trial services to the global healthcare industry. Based in Tredegar, Wales, Penn built a solid, if quiet, reputation. The company identified a growing, specialized need within the market: the manufacturing of highly potent solid-dose drugs, particularly for oncology. This was a complex and demanding niche. The playbook changed in 2007 when private equity firm LDC invested £33 million in a buyout, partnering with the management team to fuel growth. This capital injection enabled a key strategic move. In 2013, Penn opened a new, cutting-edge facility designed specifically for the contained manufacturing of these highly potent compounds. This decision positioned Penn as a leader in a high-demand field. The move paid off. In 2014, the American company Packaging Coordinators, Inc. (PCI) saw a perfect strategic fit. PCI acquired Penn Pharma for £127 million, seeking to integrate Penn's early-stage drug development and potent manufacturing capabilities into its own extensive packaging and clinical supply services. The acquisition marked the next chapter for the Welsh company, folding its specialized expertise into a larger global enterprise.